| abstract |
The present invention relates to a culture of the novel Bacillus amyloliquefaciens strain CS 61 and its use, and specifically, to a non-toxic culture of Bacillus amyloliquequicience and antioxidants, anti-inflammatory agents, including the same. And pharmaceutical compositions that inhibit the growth of antibiotic resistant pathogenic microorganisms or enteric harmful microorganisms. Cultures from the Bacillus amyloliquipsis CS61 strain of the present invention are methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, enterococcus faecalis , enteropathogenic microorganisms , yellow As it has an antimicrobial ability to effectively inhibit the growth of Staphylococcus aureus , it can be used as a pharmaceutical composition that inhibits or inhibits the growth of antibiotic-resistant pathogenic microorganisms or harmful intestinal microorganisms. Because it inhibits the production of nitric oxide, it can be usefully used as an antioxidant, an anti-inflammatory agent, an adjuvant and an antibiotic substitute. |